Novo Nordisk (NVO)
The desk's stance
On our research list, not on the slate.
What the company does
The Danish pioneer that built the modern obesity market with Ozempic and Wegovy — now navigating a two-front war: trial competition from tirzepatide (with CagriSema REIMAGINE Phase 3 data awaiting a late-2026 FDA decision) and compounder pushback that drove the March 2026 Hims distribution pact.
In short: Diabetes and obesity drugmaker. Category: GLP-1 Biopharma Duopoly Leader. Sector: Healthcare, Drug Manufacturers - General.
G-Street Value and Score
G-Street Value: $36.30, computed Oct 18, 2026 (confidence: low).
How we got there: 70% analyst leg $36.3 (3 analyst targets, credibility- and freshness-weighted, after 8% optimism discount) + 30% GainStreet factor value $116.49 (17.52× fwd EPS anchored to healthcare multiples) — capped at the analyst leg; factors never out-bull the street — analyst and factor views diverge >50%, confidence reduced. 1 analyst target has no linked source and is shown but not counted.
G-Street Score: 44 out of 100 (Weak).
- Top-line growth & guidance: 7 of 32
- Margin power: 12 of 15
- Revenue visibility & quality: 5 of 11
- Profitability & balance sheet: 15 of 24
- Capital allocation & governance: 3 of 6
- Valuation, sentiment & momentum: 2 of 12
Our current thesis
Updated Oct 17, 2026
The thesis
- Unrivaled manufacturing footprint supports long-term volume expansion across global diabetes and obesity markets.
- Pipeline optionality from oral Wegovy adoption and Phase 3 CagriSema data provides key differentiation.
- Depressed valuation of 9.5x trailing earnings offers attractive risk/reward if net pricing stabilizes.
Risks
- Eli Lilly continues to heavily outpace top-line growth and capture dominant obesity share.
- Intense U.S. pricing concessions, channel rebates, and generic semaglutide threats erode margins.
- Decelerating revenue trajectory and recent trial headwinds raise long-term terminal value concerns.
What we're watching
- Q3 2026 earnings release on November 4, 2026, focusing on net realization stabilization.
- Maintenance of critical technical support near the 52-week low of $35.12.
- U.S. volume share stabilization for Ozempic and Wegovy against Lilly's Zepbound.
Latest
NVO trades at $38.83, hovering near its 52-week low of $35.12 following sharp multiple contraction and Wall Street target cuts. While Q2 2026 revenue stabilized sequentially at DKK 78.5B and EPS beat consensus by 24%, annual top-line growth of 2.1% severely lags duopoly rival LLY (+48%). BMO and Morgan Stanley lowered targets to $40 citing gross-to-net headwinds and U.S. market share erosion ahead of Q3 earnings on November 4, 2026.
Key numbers
As of Oct 16, 2026: market cap $171.4B · revenue growth +2.1% year over year · gross margin 82.0% · net margin 35.3% · forward P/E 1.7 · next earnings Nov 4, 2026.
Analyst price targets
Published analyst targets we could trace to a named source.
- BMO Capital, Hold: $40 target (October 2026). Source: investing.com
- Morgan Stanley, Underweight: $40 target (September 2026). Source: financialmodelingprep.com
- CFRA, Sell: $38 target (September 2026). Source: investing.com
On the Gainz Lab maps
Who it does business with
- Catalent (Novo Holdings) supplies Novo Nordisk — Fill-finish capacity. Novo Holdings completed its $16.5B acquisition of Catalent, transferring key fill-finish sites directly to Novo Nordisk to lock up Wegovy pen supply.
- Eli Lilly competes with Novo Nordisk — The obesity crown. Tirzepatide and the oral Foundayo launch opened a wide lead, while Novo defends with Wegovy, oral semaglutide, and CagriSema's pending FDA review.
- Novo Nordisk supplies Hims & Hers — Wegovy via telehealth. Novo partnered with Hims & Hers in March 2026 to distribute authentic Wegovy directly through telehealth, resolving compounded semaglutide disputes.
- Novo Nordisk supplies CVS Health (Caremark) — Formulary preferred. Caremark kept Wegovy as a preferred GLP-1 on commercial formularies while negotiating rebate terms with both duopolists.